Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Palatin Technologies, Inc. is a biopharmaceutical company focused on developing receptor-specific medicines targeting the melanocortin receptor system. Its products aim to treat inflammatory, autoimmune, metabolic, and rare diseases, including obesity, dry eye disease, and inflammatory bowel conditions. The company leverages proprietary peptides and small molecules, collaborates with industry partners, and seeks regulatory approval to commercialize innovative therapies with broad therapeutic potential.
This description was generated via AI from an annual report. Updated about 1 year ago.